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Summary
 
To investigate the influence of endogenous peptides on the developmental processes that occur
during thymocyte selection, we have used monoclonal antibodies that preferentially recognize
the major histocompatibility complex (MHC) molecule I-E
 
k
 
 when it is bound to the moth cy-
tochrome 
 
c
 
 peptide (88–103). One of these antibodies (G35) specifically blocks the positive se-
lection of transgenic thymocytes expressing a T cell receptor that is reactive to this peptide–
MHC complex. Furthermore, G35 does not block the differentiation of transgenic T cells
bearing receptors for a different I-E
 
k
 
–peptide complex. This antibody recognizes a subset of
endogenous I-E
 
k
 
–peptide complexes found on a significant fraction of thymic antigen-present-
ing cells, including cortical and medullary epithelial cells. The sensitivity of G35 to minor alter-
ations in peptide sequence suggests that the thymic peptide–MHC complexes that mediate the
positive selection of a particular class II MHC–restricted thymocyte are structurally related to
the complexes that can activate it in the periphery.
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T
 
cell maturation depends on the specificity of thy-
mocyte TCRs for peptide–MHC complexes that are
expressed in the thymus (1–3). Thymocytes that fail to
transduce a signal in response to thymic MHC do not ma-
ture and instead die in the thymus. The surviving T cells
that may eventually emigrate to the periphery are said to be
positively selected. The result of this positive selection is a
repertoire of thymocytes bearing TCRs that are reactive to
self-MHC when it is bound to both foreign and endoge-
nous peptides. Before leaving the thymus cells that react
strongly with thymic peptide–MHC complexes are elimi-
nated by activation-induced cell death or negative selection
(1). Together, these processes select a peripheral TCR rep-
ertoire composed of cells that preferentially recognize self-
MHC molecules bound to foreign peptides.
The molecular basis by which the same MHC molecule
can mediate these different developmental decisions re-
mains unclear (for review see reference 4). Several factors
may influence the fate of a given thymocyte. These include
its developmental stage at the time it receives a signal, the
characteristics of the APCs that interact with it, and the na-
ture of the peptide–MHC complexes that are displayed by
the APCs. Here we employ TCR transgenic mice in
which all T cells express the same TCR to examine the in-
fluence of peptides on the positive selection of a particular
TCR specificity.
Peptides are clearly required for the positive selection of
a complete T cell repertoire, yet the precise role of peptide
sequence in these processes is not well understood (for re-
view see reference 4). Positive selection by both class I and
class II MHC molecules is inhibited by mutations that
diminish peptide loading and/or surface expression of
MHC molecules (5–10). Addition of certain peptides to fetal
thymic organ cultures restores the positive selection of class
I–restricted TCR transgenic thymocytes (11–15). Although
the peptides that can positively select a given TCR are var-
ied, many resemble (or in one case are identical to) the
peptides that can stimulate the TCR transgenic T cells in
the periphery. More recently, endogenous peptides that in-
duce the positive selection of CD8
 
1
 
 class I–restricted T
cells have been identified. Surprisingly, these self-peptides
bear little resemblance (in sequence) to the peptides that are
 
known to activate the mature TCR transgenic cells (16, 17).
Because in vitro rescue of positive selection has not been
possible for CD4
 
1
 
 T cells, studies of class II–restricted T
cells have examined class II–mediated positive selection in
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vivo. Mice that have been genetically modified so that they
express class II MHC molecules bound to a single peptide
generate a large peripheral CD4
 
1
 
 T cell population and an
unperturbed repertoire of TCR 
 
b 
 
chains (8–10, 18, 19).
However, these “single-complex mice” do not select all
TCR specificities and fail to support the development of
several specific transgenic TCRs (20–22). Thus, although a
peptide’s sequence and/or concentration may direct an in-
dividual thymocyte toward either positive or negative se-
lection, current models still fail to predict the selective
properties of an individual peptide.
To refine these models, several questions remain. In par-
ticular, what are the endogenous peptides that normally in-
duce positive selection of a particular class II–restricted
TCR specificity? How are these peptides related to the
nominal peptide(s) to which a mature T cell responds? And
finally, what is the expression level and tissue distribution
of these endogenously expressed peptides? Without such
information, it is difficult to assess how other components
of thymocyte recognition, such as affinity and coreceptor
stimulation, contribute to the distinction between positive
and negative selection.
To investigate these aspects of the role of peptide in the
class II system, we have used mAbs that recognize the class
II MHC molecule I-E
 
k 
 
only when it is bound to peptides
that resemble the COOH-terminal portion of moth cyto-
chrome 
 
c
 
 (MCC 88–103).
 
1
 
 One of these antibodies specifi-
cally blocks positive selection of TCR transgenic thymo-
cytes that bear a receptor specific for this same peptide–MHC
combination. The distribution of this antibody epitope in
the thymus indicates that this endogenous complex is present
in both the thymic cortex and the medulla. Thus, not only
are a subset of endogenous I-E
 
k
 
–associated peptides essen-
tial for positive selection, but the sequence or structure of
these endogenous peptides must be related to the peptides
that can stimulate the selected T cell in the periphery.
 
Materials and Methods
 
Antibodies
 
mAbs were generated by immunizing mice with soluble
MCC–I-E
 
k
 
 complexes and purified with a 1:1 mixture of protein
A– and protein G–sepharose (Pharmacia) from tissue culture su-
pernatants derived from bulk culture of hybridomas grown in
roller bottles, or on a CellPharm (Unisyn Technologies) using
RPMI supplemented with penicillin-streptomycin and 10% fetal
calf serum (Gemini). Purified antibodies were concentrated by
ultrafiltration, and yields were quantified by absorbance. Where
necessary, antibodies were conjugated to FITC (Molecular
Probes), biotin (Pierce), or digoxigenin (Boehringer Mannheim)
using standard protocols.
 
Mice
 
Specific pathogen-free B10.Br, C57BL/6, and AKR/J mice
were obtained from The Jackson Laboratory and crossed to mice
transgenic for the TCR derived from the T cell clone 5C.C7 (23)
 
or the T cell hybridoma A18 (24). All mice were 4–8 wk of age
or 1–3-d-old neonates. Mouse handling and experimental proce-
dures were conducted in accordance with institutional guidelines
for animal care and use.
 
Antibody Administration In Vivo
 
Male 5C.C7 TCR transgenic mice were crossed under specific
pathogen-free conditions with B10.Br females (The Jackson Lab-
oratory). Pregnant mice were removed on the day after impreg-
nation (day 0), and were injected intraperitoneally with 1 mg per
day of the indicated antibodies in 100 
 
m
 
l sterile PBS.
 
Preparation of Stromal Cells
 
Thymuses were digested for 45 min at 37
 
8
 
C with collagenase
type IV (Sigma Chemical Co.) and dissociated by vigorous pipet-
ting. Stromal cell cultures were then grown for 5–8 d in selective
media (25) and either incubated with thymocytes for the in
 
 
 
vitro
positive selection assays or removed from the plate by a combina-
tion of collagenase treatment and vigorous pipetting for FACS
 
®
 
analysis.
 
In Vitro Positive Selection Assays
 
5C.C7 Only Assays.
 
Unsorted 5C.C7 cells from 5C.C7/
C57BL/6 TCR transgenic, 4-wk-old females were isolated by
passing the cells through nylon mesh and washing. These cells
were then incubated with thymic stromal cell cultures at 37
 
8
 
C for
the indicated times.
 
A18/5C.C7 Assays.
 
Purified unselected CD4
 
1
 
8
 
1
 
 thymo-
cytes were isolated from positively selecting strains by four-color
flow cytometry. Dead thymocytes and non-T cells were ex-
cluded by gating out dead cells staining positive for propidium
iodide or thymic APCs that were positive for class II MHC or
B220. 2 
 
3
 
 10
 
6
 
 CD4
 
lo/
 
1
 
CD8
 
lo/
 
1
 
CD69
 
2
 
 cells were sorted from
each transgenic mouse. 2 
 
3
 
 10
 
5
 
 immature thymocytes per well
were incubated with 5–8-d-old stromal cell cultures for 2.5 d.
Cells were removed by incubation at 4
 
8
 
C in PBS/2% FCS/2.5
mM EDTA followed by vigorous pipetting. Thymocytes were
subsequently stained for the transgenic 
 
a
 
 or 
 
b
 
 chain, CD4, CD8,
and class II MHC/B220.
 
FACS
 
®
 
 Analyses
 
In Vivo Positive Selection Assay.
 
Cells from neonatal thymuses
were isolated by pushing whole thymuses through metal
screens. Cells were stained with CD4-PE, CD8-APC (Caltag),
KJ25, followed by anti–hamster Texas Red, and rabbit anti-
5C.C7 V
 
a
 
 followed by anti–rabbit-FITC. Dead cells were ex-
cluded from analyses by size and failure to exclude propidium io-
dide.
 
In Vitro Positive Selection Assay.
 
Cells were stained with anti-
V
 
a
 
11–FITC (clone RR8.1; PharMingen) or anti V
 
b
 
8 (clone
F23.1-FITC; gift from Dr. Irving Weissman, Stanford University,
Stanford, CA), anti–I-A
 
k/b
 
-biotin, B220-biotin followed by strep-
tavidin-PE (all from PharMingen), CD4-APC (clone GK1.5;
Caltag Labs.), and CD8-Texas Red (Elizabeth Kerr, Stanford
University) before analysis on a modified FACS
 
®
 
 II dual laser
flow cytometer (Becton Dickinson) and analyzed using FACS
 
®
 
Desk software (Beckman Center Shared FACS Facility, Stanford,
CA). Where necessary, stromal cells and dead cells were excluded
from analysis by gating out propidium iodide– and class II MHC/
B220–positive cells. Stromal cells were stained with anti I-E
 
k
 
(14.4.4S-biotin) followed by avidin–Texas Red, B220-APC
(clone RA3-6B2), CD3-PE (clone 145-2C11) (all PharMingen,
San Diego, CA), and G35 or D4 directly conjugated to FITC.
 
1
 
Abbreviation used in this paper:
 
 MCC, moth cytochrome 
 
c. 
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ELISA
 
Plates were coated with 10 
 
m
 
g/ml of the anti–I-E
 
k
 
 antibody
G14 (Reay, P.A., unpublished data). Soluble propidium iodide–
linked I-E
 
k
 
 (26) was incubated for 3 d at 37
 
8
 
C in citrate phos-
phate buffer, pH 5.0, in the presence of a 50-fold molar excess of
each of the 220 single amino acid substituted peptide variants
(27). After neutralization, 50 
 
m
 
l of a 10 
 
m
 
M solution of each vari-
ant-complex was captured in the presence of 2% BSA. After ex-
tensive washing, biotinylated G35 was titrated on each complex,
and the amount bound was assessed using alkaline phosphatase–
conjugated avidin (Biomeda). The amount of G35 resulting in
one-half maximal signal was determined by curve fitting and ex-
trapolation.
 
Immunohistochemistry
 
Light and electron microscopic immunohistochemical studies
were performed as described previously (28, 29). Digoxigenin-
conjugated mAbs were detected with horseradish peroxidase–
conjugated Fab fragments of goat anti-digoxigenin antibodies
(Boehringer Mannheim). Light microscopic studies were done
with fresh frozen sections fixed by immersion in cold acetone.
Ultrastructural immunohistochemistry was performed on thin
slices of thymus tissue previously fixed by vascular perfusion with
4% paraformaldehyde. After demonstration of peroxidase activity
with hydrogen peroxide and 3,3
 
9
 
 diaminobenzidine, these tissue
sections were treated with OsO
 
4
 
, and then processed for conven-
tional electron microscopy.
 
Purification of Thymic I-E
 
k
 
Thymuses were removed from 327 B10.Br mice and placed
on ice in PBS. Thymuses were dissociated by dounce homogeni-
zation and lysed in PBS containing protease inhibitors (2 mM
PMSF, 100 
 
m
 
M iodoacetamide, 5 
 
m
 
g/ml aprotinin, 10 
 
m
 
g/ml leu-
peptin, 10 
 
m
 
g/ml pepstatin A, 3 ng/ml EDTA, and 0.2% sodium
azide) and 2% Mega-9 detergent (Sigma Chemical Co.) for 1 h.
The detergent lysate was spun at 100,000 
 
g
 
 for 1 h to remove nu-
clei and insoluble protein. The lysate was then cleared by filtra-
tion through 0.22-
 
m
 
m filters (Corning) and run serially over five
cyanogen bromide–conjugated antibody columns in the follow-
ing order: CN-Br conjugated to total mouse IgG, CN-Br D4,
CN-BR-G35A, CN-Br G35 B, and CN-Br 14.4.4. Each col-
umn was washed extensively with detergent containing Tris, pH
8.0, plus 150 mM NaCl, then Tris, pH 8.0, plus 150 mM NaCl,
Tris, pH 8.0, plus 0.5 M NaCl, Tris, pH 8.0, and finally eluted
with acetic acid, pH 2.7, containing 10 ng/ml leupeptin as a car-
rier. Fractions were acidified to 2.1 with glacial acetic acid
and boiled for 10 min to release peptides. Fractions were then
separated on a Millipore Ultrafree CL device with a 5,000 dalton
cut-off (Millipore UFC4LCC25).
 
Western Blotting Analysis/SDS-PAGE
 
SDS-PAGE was performed according to standard methods.
Samples were collected from the top (
 
.
 
5 kD) portion of Milli-
pore Ultrafree CL devices and resuspended in running buffer
containing SDS and the reducing agent 
 
b
 
-ME. The 12% gels
with the 14.4.4 and G35 samples were prepared and run in paral-
lel. Proteins were transferred overnight at 4
 
8
 
C onto Hybond filter
paper that was then blocked with 2% dehydrated milk/PBS/0.1%
Tween solution. The blots were incubated with polyclonal rabbit
anti-I-E
 
k
 
 serum in blocking solution, washed, and incubated with
goat anti–rabbit HRP (Biomeda). Horseradish peroxidase activity
was visualized with the ECL detection kit (Amersham).
 
Microbore HPLC Analysis of Peptides
 
Fractions were concentrated by lyophilization and peptides
from equivalent amounts of total I-E
 
k
 
 were separated by reverse-
phase HPLC. Samples were separated on a C18 column (1 
 
3 
 
150
mM; Reliosil) with a linear water/acetonitrile gradient in 0.1%
TFA (0–45% acetonitrile, 30 min) at a flow rate of 75 
 
m
 
l/min.
Chromatograms are displayed as absorbance at 209 nm versus re-
tention time in minutes.
 
Results
 
G35 Blocks Positive Selection of I-E
 
k
 
/MCC–reactive T Cells
In Vivo.
 
We have generated several mAbs that specifically
recognize the class II MHC molecule I-E
 
k
 
 bound to a pep-
tide derived from MCC 88–103. Two of these antibodies
(D4 and G35) bind to the same region of this complex as T
cells and inhibit the activation of T cells that recognize this
complex (Reay, P.A., unpublished data). We wondered if
these antibodies might also inhibit the activation events in-
volved in thymic selection.
To address this question, we injected mice with G35,
D4, and PBS and analyzed the effects of these antibodies on
the development of I-E
 
k
 
–MCC-specific thymocytes that
express the TCR transgene 5C.C7. To provide nontrans-
genic internal controls, 5C.C7 TCR transgenic males were
crossed to nontransgenic females to generate litters in
which 50% of the progeny were transgenic. The pregnant
females were injected intraperitoneally each day (from day
15 of gestation until birth) with either 1 mg of antibody or
PBS. On day 21, thymuses were harvested from the neo-
nates and four-color flow cytometry was used to determine
the transgenic status and CD4 versus CD8 profile of each
mouse (Fig. 1 A). In transgenic pups, the percentage of
identified transgene-positive cells was 
 
z
 
80% in all treat-
ment groups; the rest of the cells were presumably imma-
ture cells that lacked detectable TCR expression or thymic
APCs.
Analysis of several pups from each mother showed that
the G35-treated transgenic mice are almost devoid of
Figure 1. Effect of G35 on the
selection of 5C.C7 transgenic
thymocytes. (A) Distribution of
5C.C7-a chain and KJ25 (Vb3)
determinants on thymocytes de-
rived from transgenic (left) or
nontransgenic (right) pups. (B)
Distribution of CD4 and CD8
on separate populations of cells
derived from transgenic or non-
transgenic pups exposed in utero
to G35, PBS, or D4 as indicated.
Numbers refer to the percentage
of total live transgenic or non-
transgenic thymocytes that fall
within each boxed population. 
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CD4
 
1
 
8
 
2
 
 cells, whereas the nontransgenic pups produce
normal numbers of CD4
 
1
 
8
 
2
 
 cells. Representative plots of
CD4 versus CD8 from one nontransgenic and one trans-
genic neonate from mothers that were injected with PBS
or the relevant mAb are displayed in Fig. 1 B. Because even
identically treated littermates often exhibit substantial varia-
tion in the percentage of cells in each thymic subset, the
average percentage of total live cells that fell into the CD4
 
1
 
or CD4
 
1
 
8
 
1
 
 
 
gates in each treatment group was computed
and plotted (Fig. 2). G35 treatment of transgenic mice
causes a fourfold reduction in the percentage of positively
selected CD4
 
1
 
8
 
2
 
 thymocytes present at day 21, while
modestly increasing the relative proportion of CD4
 
1
 
8
 
1
 
thymocytes. Notably, treatment with G35 antibody has no
reproducible or significant effect on the thymocyte profiles
of the nontransgenic littermates of the transgenic mice.
Similarly, injections with PBS or the isotype-matched con-
trol antibody, D4, did not perturb thymic development in
transgenic or nontransgenic mice. All transgenic and non-
transgenic pups had equivalent circulating levels of G35
(45–68 
 
m
 
g/ml) and D4 (88–113 
 
m
 
g/ml).
 
G35 Blocks Positive Selection of I-E
 
k
 
/MCC–reactive T Cells
In Vitro.
 
In previous studies, injection of anti–class II
MHC mAbs that are peptide independent inhibited posi-
tive selection of CD4
 
1
 
 T cells (30, 31). This effect may
have resulted from a simple blockade of TCR access to
MHC or, alternatively, long-term antibody treatment may
have caused general downregulation of MHC or killed the
MHC-bearing cells required for positive selection. Because
we were interested in peptide-specific effects of antibody
treatment we wanted to exclude the possibility of complete
ablation of positive selection. Thus, we examined the effect
of anti-MHC antibodies in vitro by using short-term thy-
mic stromal cell explant cultures (25).
Thymic epithelial cells were isolated from thymuses taken
from 3–4-wk-old mice and grown in media that selectively
kills fibroblast-derived cells to enrich for thymic stromal
epithelial cells (32). To provide unmanipulated immature
CD4
 
1
 
8
 
1
 
 cells bearing the 5C.C7 receptor, TCR transgenic
mice were crossed to a nonselecting background (C57BL/6).
The majority of the immature thymocytes from these mice
are immature CD4
 
1
 
8
 
1
 
CD692 TCRlow/intermediate cells that
fail to initiate CD8 downregulation even after 52 h in cul-
ture (Baldwin, K.K., unpublished data and reference 33). In
contrast, when these immature thymocytes are cocultured
with thymic stromal cells that express I-Ek, they begin to
downregulate CD8 after 26 h (Fig. 3, a and d). After 52 h,
the thymocytes still attached to the I-Ek–positive stromal
cells are almost entirely mature CD4182 cells (Fig. 3, b and
e). Additional FACS® analyses show that these cells express
the high levels of CD69 and low levels of HSA that are
characteristic of differentiated CD4182 thymocytes (Bald-
win, K.K., unpublished data).
Importantly, as in the in vivo experiments, the presence
of 50 mg/ml of G35 antibody inhibits the positive selection
of the transgenic thymocytes but does not affect the thy-
mocytes on nonselecting stromal cells (Fig. 3, c and f). The
effects of G35 on selection do not increase at antibody con-
centrations of 100 mg/ml, are more modest at 33 mg/ml,
and are undetectable at 10 mg/ml (data not shown). Fur-
thermore, G35 treatment does not affect the viability or
MHC expression levels of the cells in the culture (data not
shown). We conclude that G35 inhibits positive selection
of thymocytes in vitro by blocking their access to I-Ek–
peptide complexes rather than by killing APCs or inducing
MHC downregulation.
Blockade by G35 Is Specific to TCRs That Recognize
MCC–I-Ek Complexes. The fact that G35 does not influ-
ence the development of nontransgenic CD4 thymocytes
suggests that it may recognize only the subset of thymic
peptides that is responsible for selecting this particular
range of TCR specificity. Alternatively, G35 may block se-
lection by binding to all or most thymic I-Ek molecules re-
gardless of their bound peptides. In this model, nontrans-
genic thymocytes would not be visibly affected because
they could mature on non–I-Ek class II MHC molecules
such as I-Ak. To distinguish between these models, we ex-
amined the influence of G35 on the development of thy-
mocytes from mice transgenic for a different TCR that re-
quires I-Ek for positive selection yet does not cross-react
with MCC (24). These mice express a TCR derived from
the T cell clone A18, which is specific for a peptide derived
from the murine C5 complement protein that is present in
the B10.Br strain. Since the C5 protein is deleted in the
Figure 2. Effects of antibody
treatment on thymocyte subpop-
ulations. The figure shows the
average percentage of total live
cells with the indicated CD4/
CD8 expression patterns from
three to five transgenic or non-
transgenic neonates born to
mothers treated with G35 (white
bars) or PBS (black bars). Error
bars represent 1 SD.
Figure 3. G35 blocks 5C.C7 transgenic T cell differentiation in vitro.
Analysis of CD4/8 expression on thymocytes removed from stromal cell
cultures derived from B10.Br (top) or C57BL/6 (bottom) mice after 26 (a
and d) or 52 h (b, c, e, and f). G35 was added to a final concentration of
50 mg/ml in c and f. Numbers on plots refer to the percent of total live
transgenic thymocytes that fall within each boxed population.17 Baldwin et al.
I-Ek–bearing strain AKR/J, A181 thymocytes are positively
selected in AKR/J backgrounds but negatively selected on
B10.Br. Rather than crossing these mice to a nonselecting
background (C57BL/6) that would also introduce a poten-
tial source of the negatively selecting C5 protein, we mod-
ified the in vitro positive selection assay.
Instead of taking immature thymocytes from nonselect-
ing strains, we isolated immature (CD4181) unactivated
(CD69lo) thymocytes from positively selecting strains by
FACS®. To standardize the results between the two trans-
genic mouse strains, and to test the validity of the modified
in vitro system, this sorting procedure was performed on
cells from both the 5C.C7 3 B10.Br and A18 3 AKR/J
positively selecting lines. As shown in the previous experi-
ments, the immature thymocytes from both strains down-
regulate CD8 only in the presence of I-Ek (Fig. 4 A).
Furthermore, G35 efficiently blocks 5C.C7 thymocyte dif-
ferentiation at the CD4181 stage. In contrast, although
A18 thymocyte development depends on I-Ek expression,
G35 does not influence A18 T cell development (Fig. 4 A).
The results of three independent experiments are plotted
in Fig. 4 B. Because the ability of the stroma to support dif-
ferentiation varies among experiments, the data are
presented as the percentage of live, transgene-positive,
CD4182 cells relative to CD4181 cells (termed selective
index), normalized to the average CD4182/CD4181 ratio
for the untreated I-Ek–positive samples. These data show
that G35 blocks development in a TCR-specific manner.
G35 Stains a Subset of Class II MHC Positive Cells. To
conclude that the TCR-specific nature of the G35 block-
ade results from recognition of the self-peptide–MHC
complexes that mediate positive selection of thymocytes
bearing the 5C.C7 but not the A18 TCRs, it is necessary
to show that G35 recognizes only a subset of thymic pep-
tide–MHC complexes. To determine the localization and
expression level of the G35 epitope, we examined the dis-
tribution of G35, D4, or 14.4.4S antibodies on frozen sec-
tions of thymus, spleen, and lymph node derived from
B10.Br mice (Fig. 5 A). As shown in Fig. 5 A, a, 14.4.4S,
which detects I-Ek in a peptide-independent manner, reacts
homogeneously with both the cortical and medullary areas,
although it exhibits a more confluent pattern within the
medulla. In contrast, the determinant for G35 is clearly ex-
pressed at higher levels by a subset of cells within the thy-
mic medulla, although a lower level of G35 staining of cor-
tical stromal processes and the subcapsular region was
routinely observed (Fig 5 A, b). The 14.4.4S antibody ex-
hibits widespread reactivity in lymph node and spleen, la-
beling both B and T cell–dependent areas (Fig 5 A, d and
g). Labeling of these tissues with G35 was more heteroge-
neous; staining was restricted to follicular structures in the
lymph node cortex, and to B cell–dependent areas of
splenic white pulp. Reactivity of G35 with T cell–depen-
dent areas of lymph node or spleen was weak and restricted
to a few scattered cells. B10.Br thymic tissue failed to react
with the D4 mAb (Fig. 5 A, c) and no G35 reactivity with
tissues from C57BL/6 mice was detected (data not shown).
G35 staining is more intense in some regions of the thymus
than others, even when these areas express similar levels of
I-Ek. Thus, all I-Ek–bearing cells do not bind equally well
to G35. To determine which cell types express the G35-reac-
tive peptide–MHC complexes, we performed ultrastruc-
tural analyses of thymic sections. These analyses demon-
strated that G35 reactivity is associated with the membranes
of all three morphologically-defined thymic APC types, in-
cluding cortical epithelium, medullary epithelium, and
dendritic cells (Fig. 5 B). Staining is most intense on den-
dritic cells, intermediate on cortical epithelium, and weak
but detectable on medullary epithelium. Thus, although
G35 staining is not restricted to a particular APC subset,
expression of the relevant complexes may be enhanced in
cortical epithelial cells as compared with medullary epithe-
lial cells.
To further examine the heterogeneity of G35 reactivity
among thymic stromal cells and to confirm that the G35
epitope was expressed by class II–positive cells in the thy-
mus, we used four-color flow cytometry. Immortalized B
cells from I-Ek–positive mice (CH27 cells), cells from
whole thymuses, and thymic stromal cell cultures were an-
alyzed for expression of the 14.4.4, CD3, B220, and G35
Figure 4. Inhibition of posi-
tive selection by G35 is specific
for the MCC-I-Ek–restricted
TCR. (A) Immature thymo-
cytes from 5C.C7/B10.Br or
A18/AKR/J TCR transgenic
mice were cultured with thymic
stromal cells from C57BL/6
(top) B10.Br (middle) or AKR/J
(bottom) mice. Numbers on plots
refer to the percentage of total
live transgenic thymocytes that fall within each boxed population. (B) Analysis of the effects
of G35 on production of CD41 cells. The selection index was generated for each treatment
group by computing the average percentage of CD4182/CD4181 for untreated, I-Ek–posi-
tive stromal cells on each day and comparing the average percentage of CD4182/CD4181
from other samples to that number. Shown are the pooled results of two independent exper-
iments, each with three to six replicates of identically treated stromal cells (the exact number
is printed on each bar). Conditions: C57BL/6 stroma, white bars; B10.Br stroma, dark gray
bars; B10.Br stroma plus G35 50 mg/ml, light gray bars; and B10.Br stroma plus D4 50 mg/
ml, hatched bars. Error bars represent 1 SD.18 Endogenous Peptides and Positive Selection
or D4 epitopes. Importantly, the I-Ek-expressing B cell line
CH27, which expresses a diverse array of peptides, exhibits
no G35 reactivity. Thus G35 cannot react with all endog-
enously produced I-Ek complexes (Fig. 6 a). In contrast,
when these cells are incubated overnight with MCC pep-
tide, all of the cells exhibit strong G35 reactivity (Fig. 6 a).
These staining levels were used to assess the percentage of
cells from other tissues that could be recognized by G35.
Approximately 20% of freshly isolated class II–positive thy-
mic cells from B10.Br but not C57BL/6 mice express the
G35 determinant (Fig. 6 c). Close to 40% of I-Ek–positive
cells from this particular thymic stromal cell culture bind
specifically to the G35 antibody (Fig. 6 b). Neither G35 nor
D4 labels CD31 cells and D4 fails to stain any of the thymic
stromal cells (data not shown). Thus, a subset of thymic and
peripheral I-Ek–positive cells are preferentially labeled by
G35. Because G35 stains only a subset of cells that all express
equivalent levels of I-Ek, it must preferentially label a subset
of peptide–MHC complexes that are unevenly distributed
on different cells. In addition, the low affinity of this anti-
body for MCC–I-Ek complexes (with respect to the similar
antibody D4) and the weak overall staining of these tissues
suggest that nonspecific binding of G35 to all thymic I-Ek–
peptide complexes is unlikely to be the mechanism for the
TCR-specific blockade of thymic differentiation.
Purification of I-Ek–bound Peptides. To directly compare
the peptides recognized by G35 with those bound to all
I-Ek molecules in the thymus, we isolated thymuses from 327
B10.Br and B10.A (a related I-Ek–positive congenic strain)
mice. Using a modified version of established MHC purifi-
cation protocols (34–36), we isolated thymic I-Ek mole-
cules that were bound by G35 or by the peptide-nonspe-
cific antibody 14.4.4. Two G35 columns were run in series
and the unbound lysate was then passed over the 14.4.4
column. Western blotting was used to determine the
amount of MHC present in each fraction. The first G35
column bound z670 ng (11 pmol) of I-Ek, whereas the
second G35 column yielded no detectable MHC (Fig. 7
A). The pooled fractions from the 14.4.4 column bound to
z7 mg of I-Ek (Fig. 7 A). Thus although both G35 and
14.4.4 can recognize the endogenous peptide–MHC com-
plexes displayed on thymic APCs, G35 is less efficient at re-
moving these complexes from thymic extracts. These data
argue that G35 recognizes a finite and unique subset of thy-
mic I-Ek–peptide complexes.
To confirm that G35 recognizes a unique subset of thy-
mic I-Ek–peptide complexes, and to estimate the peptide
diversity in this preparation, we analyzed the peptides
eluted from the thymic I-Ek by HPLC. Equivalent
amounts of G35, 14.4.4, or a blank solution containing the
Figure 5. G35 reactivity with thymus and peripheral lymphoid tissues.
(A) Frozen sections of thymus (a–c), lymph node (d–f), and spleen (g–i)
were labeled with 14.4.4S (a, d, g), G35 (b, e, h), D4 (c), or an irrelevant
mAb (f, i). PC, T cell–dependent paracortical area; RP, red pulp and
white pulp. Original magnification: a–i, 345–55. (B) Ultrastructural anal-
ysis of G35 reactivity with thymus tissue. Labeling was associated with (a)
cortical epithelium, (b) medullary epithelium (desmosome indicated by
arrowhead, characteristic cystic structures indicated by asterisk), and (c)
dendritic cells (characteristic bullate processes indicated by asterisks).
Original magnification: a, 38,400; b, 34,950; c, 38,050.
Figure 6. G35 recognizes endogenous I-Ek–peptide complexes on a
subset of thymic APCs. Levels of G35 expression on live, large
CD3214.4.41 cells. (a) Cells from B10.Br (black line) or C57BL/6 (gray
line) thymuses. (b) The staining of a stromal cell culture derived from
B10.Br mice. (c) G35 expression on CH27 B cells pulsed overnight with
10 mM MCC 88–103 peptide (black line) or PBS (gray line). The per-
centage of cells with fluorescence greater than the intercept of the dashed
lines was ,2% in negative controls, 20% in a, 41% in b, and 97% in c.19 Baldwin et al.
carrier peptide and protease inhibitor leupeptin were sepa-
rated on a C18 column with a linear water/acetonitrile gra-
dient in 0.1% TFA. The portion of the gradient in which
peptides are known to elute is displayed in Fig. 7 B. Com-
parison of the G35 and 14.4.4 chromatograms reveals the
presence of several peaks that are unique to each sample.
For example, at 17.37 min, a triplet peak unique to the
G35 sample appears, whereas the 14.4.4 sample has a sin-
glet at 18 min. The peptide-rich region between 20 and 25
min is extremely different in the G35 and 14.4.4 samples as
well. The complexity of the 14.4.4 trace resembles the
multipeak smears observed in other studies of 14.4.4-reac-
tive I-Ek where sequencing of the peptides from these peaks
reveals a diverse spectrum of peptide species (34, 36). In
contrast, the number of peptide-like peaks in the G35 col-
umn is reduced, although more complex than would be
expected for a single peptide species. Thus, G35 recognizes
a unique, multipeptide subset of the thymic I-Ek–peptide
complexes that is required for the positive selection of
5C.C7 CD41 T cells.
Epitope Map of G35. Because the binding of G35 to
this subset of thymic MHC–peptide complexes blocks pos-
itive selection, the characteristics and degeneracy of G35
recognition are interesting with respect to the range of en-
dogenous peptides that mediate the positive selection of
this TCR specificity. To assess the tolerance of G35 to sub-
tle changes in peptide sequence, we performed an ELISA
to measure antibody reactivity with I-Ek bound to each of
a complete replacement set of monosubstitutions of the
MCC epitope (27).
G35 recognition is more degenerate than the recogni-
tion by the 5C.C7 TCR, although less so if partial agonis-
tic or antagonistic reactivities are also taken into consider-
ation (Fig. 8). These observations suggest that although
G35 cannot recognize most I-Ek–binding peptides, it may
be able to efficiently recognize nearly every peptide–I-Ek
complex to which 5C.C7 can respond. G35 may recognize
other complexes that the 5C.C7 TCR can bind to only
weakly as well as those with which 5C.C7 fails to interact.
Although the G35 antibody is tolerant to alterations in the
NH2 terminus of MHC-bound peptide, its specificity is
very similar to the 5C.C7 TCR at the COOH terminus,
particularly at residues 101 and 102. It is difficult to esti-
mate the fraction of bound peptides that can be recognized
by G35, but consideration of the restriction at peptide posi-
tions 98, 99, 101, and 102 that are not involved in I-Ek
binding (14, 11, 3, and 5 residues of 20 tolerated, respec-
tively) suggests a figure in the range of 1–2%. In addition,
the variants that can stimulate the 5C.C7 T cell clone to
produce IL-3 (including residues that antagonize stimula-
tion by MCC complexes) are quite similar to those seen by
G35, especially at the residues 101 and 102. These results
suggest that the endogenous peptide antigens recognized
by G35 must be very similar to MCC, particularly at the
COOH-terminal residues.
Discussion
In summary, the G35 antibody blocks the positive selec-
tion of thymocytes expressing the 5C.C7 TCR but does
not affect the differentiation of other I-Ek–restricted thy-
mocytes. The distribution of G35 staining in the thymus
and in the peripheral tissues shows that the antibody differ-
entially recognizes certain thymic I-Ek–peptide complexes.
Figure 7. Purification of thy-
mic I-Ek peptide complexes. (A)
Western blot of 12% acrylamide
gel with polyclonal rabbit anti–
I-Ek antisera. 1/60 of each frac-
tion (denoted E1–5) from the
first G35 column, the 14.4.4.
column or the indicated amount
of soluble I-Ek (sIEk) was run in
each lane as noted on the figure.
(B) HPLC chromatograms of the
second fraction of the peptide
eluates (in carrier solution) from
the G35 or 14.4.4 columns, as
noted. Carrier is 10 ng/ml leu-
peptin in 0.2 N acetic acid.20 Endogenous Peptides and Positive Selection
Biochemical isolation of these complexes shows that they
comprise a finite and unique subset of total thymic I-Ek–
peptide complexes. We conclude that this antibody blocks
thymocyte development by binding to the endogenous
complexes that are required for positive selection of this
particular MCC-reactive T cell clone.
Two additional conclusions may be inferred from these
data. First, the fact that another I-Ek–reactive T cell clone
(A18) and most nontransgenic CD41 thymocytes develop
normally in the presence of G35 suggests that different
TCR specificities are selected on different subsets of thy-
mic peptide–MHC complexes. Second, the recognition
properties of G35 indicate that endogenous, positively se-
lecting peptides are likely to be structurally related to the
peptides that can stimulate mature T cells in the periphery.
What is the relationship between the endogenous pep-
tide–MHC complexes that normally mediate the positive
selection of a class II MHC–restricted receptor and those
that can activate it in the periphery? The G35 data suggest
that sequence similarity may play a role, at least in class II
MHC–mediated positive selection. In the class I system,
however, peptide sequence may be less instructive. In the
experiments of Hogquist et al. (16) and Hu et al. (17), pep-
tides were purified from class I MHC molecules derived
from thymic epithelial or other cell lines and screened for
their ability to positively select TCR transgenic thymocytes
in vitro. Surprisingly, these peptides did not resemble the
nominal peptide antigens for the receptors they studied.
However, these endogenous peptides are likely to be dif-
ferent from the peptides that allow positive selection to oc-
cur in a normal animal for two reasons. First, because the
class I MHC molecules expressed by the thymic APCs are
improperly folded due to the mutations that facilitate pep-
tide loading, they are expressed at artificially low levels.
Second, to rescue selection, the peptides must be added to
the cultures at extremely high concentrations that are un-
likely to be approximated by the endogenous peptide ex-
pression in these cells. In fact, studies of APCs have shown
that thousands of different peptides are typically expressed
by a given cell type and that even the most abundant pep-
tides typically do not comprise more than a few percent of
the total (34–36). Thus, the findings using G35 may be
more representative of the normal case in which peptide
sequence and/or structure do play an important role in de-
termining the consequences of TCR-peptide–MHC inter-
actions in the thymus.
Although we do not yet know the exact sequences of
the peptides that G35 recognizes, we do have an estimate
of their abundance and diversity. The HPLC analyses of
G35- and 14.4.4 reactive peptide–MHC complexes reveal
that although G35 peptides are likely to be less diverse than
14.4.4 they still contain a number of different species (Fig.
7). The 10-fold difference in yield between the two col-
umns suggests that G35-reactive peptides do not comprise
more than 10% of the total peptides displayed on the cell
surface. In fact, of the several predominantly displayed pep-
tides identified in previous studies (34), none interact with
G35 when bound to I-Ek (Baldwin, K.K., unpublished
data). Thus, G35 probably interacts with peptides that are
less abundant in the thymus than those previously identi-
fied.
These data not only underscore the potential importance
of peptide sequence in thymic selection, they also provide
some insight into the possible role of different cell types in
these events. Several lines of evidence have suggested that
radiation-resistant cortical thymic epithelial cells are re-
quired for positive selection (37–44) and that thymic med-
ullary epithelium and bone marrow–derived cells induce
negative selection far more efficiently than do cortical epi-
thelial cells (45–50). However, in some experimental sys-
tems, cultured thymic epithelial cells can induce deletion
(51–57), whereas some fibroblast-derived cells may mediate
inefficient positive selection (58–60). One proposed diffi-
culty in interpreting these results stems from the possibility
that the pool of endogenous peptides displayed on the sur-
face of these thymic APCs may have been different in the
various experiments. Other sequence-level investigations of
peptide expression in different tissues have not found sig-
nificant differences between tissues or between cell types in
the thymus (34). However, these analyses are technically
Figure 8. G35 sensitivity to I-Ek bound to single substitution peptide
variants. Each circle represents a different peptide; as keyed, the number
on the left indicates the amino acid that was replaced and the letters indi-
cate which amino acid was substituted in each position. Replacement
amino acids are ordered by rough chemical similarity. Only residues that
do not affect MHC binding were analyzed. (A) Recognition by mAb G35.
Black circles represent from 81 to 100% of G35 reactivity to MCC–I-Ek
complex activity and each shade of gray represents a 20% decrease in
activity as calculated by estimating the concentration of G35 necessary to
achieve the half maximal signal from the WT MCC–peptide complexes.
(B) Interaction with 5C.C7 TCR. Gray circles represent peptides that
produce detectable levels of IL-3 when used to stimulate a 5C.C7-bear-
ing cell line as indicated. Hatched circles, peptides that antagonize the
stimulation of the cell line by WT MCC peptide–I-Ek complexes; white
circles, peptides that did not antagonize or stimulate the 5C.C7 cell line.21 Baldwin et al.
very difficult and can quantify only the most abundant pep-
tides bound to a particular MHC molecule in a given cell-
type preparation. Based on these data, it is formally possible
that thymic cortical epithelial cells express a small amount
of a special peptide that permits them to induce positive se-
lection. Alternatively, these cells may have another feature
that predisposes them to induce positive rather than nega-
tive selection.
Our data suggest that special thymic peptides are not re-
sponsible for the unique ability of cortical epithelial cells to
induce positive selection. If there were such a special pep-
tide, G35 should block positive selection of all T cells,
which it does not. In addition, G35 staining should be most
intense in the thymic cortex. Instead, G35 staining is stron-
ger in the thymic medulla than in the cortex, even when
normalized for the overall MHC expression level. Despite
this increased staining, we have not detected any negative
selection of 5C.C7 thymocytes in the thymus. Thus, either
the peptides that G35 recognizes in the medulla differ from
those in the cortex, or cortical cells have peptide-indepen-
dent unique qualities that permit efficient positive selec-
tion. However, without medullary and cortical cell–spe-
cific peptide sequence, we cannot distinguish between
these alternatives.
Where else are these potentially weakly stimulatory
complexes expressed? Staining of the peripheral lymphoid
tissues with G35 indicates that these endogenous peptide–
MHC complexes are found in both the spleen and lymph
nodes. In addition, the peripheral staining varies in different
regions of the same lymph node or spleen section even
when relative levels of class II MHC are taken into account
(Fig. 5). Thus, different APCs can express different pep-
tide–MHC complexes even when they are closely associ-
ated in a single tissue. Although tissue-specific expression
patterns have been noted previously (29, 61, 62), our data
are among the first to suggest that the peptides that are re-
sponsible for positive selection in the thymus may also be
expressed by cells in the periphery at similar (or higher)
levels. In addition, recent reports from animals that lack pe-
ripheral MHC molecules have suggested that signaling in-
duced by self-peptide–MHC complexes is required for
maintenance of peripheral T cell pools (64–67). Therefore,
it is possible that the complexes recognized by G35 in the
periphery serve this function for mature 5C.C7 T cells. If
so, additional studies using G35 might also provide clues
about the identity, affinity for TCR, and localization of
such complexes.
We gratefully acknowledge David King for help with the microbore HPLC analyses. We also thank Nelida
Prado for animal husbandry; Dr. William Ho (University of Washington, Seattle) for help with FACS®
analyses; Drs. Brigitte Stockinger and Tomas Zal (both from the National Institute for Medical Research,
London, UK) for providing us with the A18 TCR transgenic mice; Drs. Barbara Fazekas de St. Groth
(Centenary Institute of Cancer Medicine and Cell Biology, New South Wales, Australia) and William Ho
for generating and characterizing the 5C.C7 TCR transgenic mice; and Drs. Irving Weissman and Anis
Sen-Majumdar for help in establishing the thymic stromal cell cultures.
K.K. Baldwin was a Howard Hughes Predoctoral Fellow. L.C. Wu is presently supported by a fellowship
from the Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation and previously by an
Immunology Training Grant. The Howard Hughes Medical Institute provided postdoctoral support for
P.A. Reay and support for this project in the laboratory of M.M. Davis. Additional support for A. Farr was
provided by NIH grants AI24137 and AG04360.
Address correspondence to Mark M. Davis, Beckman Center, Unit in Molecular and Genetic Medicine,
Stanford University School of Medicine, Stanford, CA 94305-5428. Phone: 650-723-7962; Fax: 650-498-
7771; E-mail: mdavis@cmgm.stanford.edu
K. Baldwin’s present address is H.H.M.I./Center for Neurobiology and Behavior, College of Physicians and
Surgeons, Columbia University, 701 West 168th St., New York, NY 10032.
Received for publication 27 April 1998 and in revised form 1 October 1998.
References
1. Sha, W.C., C.A. Nelson, R.D. Newberry, D.M. Kranz, J.H.
Russell, and D.Y. Loh. 1988. Positive and negative selection
of an antigen receptor on T cells in transgenic mice. Nature.
336:73–76.
2. Kisielow, P., H.S. Teh, H. Bluthmann, and H. von Boeh-
mer. 1988. Positive selection of antigen-specific T cells in
thymus by restricting MHC molecules. Nature. 335:730–723.
3. Berg, L.J., A.M. Pullen, B. Fazekas de St. Groth, D. Mathis,
C. Benoist, and M.M. Davis. 1989. Antigen/MHC-specific
T cells are preferentially exported from the thymus in the
presence of their MHC ligand. Cell. 58:1035–1046.
4. Bevan, M.J. 1997. In thymic selection, peptide diversity gives
and takes away. Immunity. 7:175–178.
5. Hogquist, K.A., M.A. Gavin, and M.J. Bevan. 1993. Positive
selection of CD81 T cells induced by major histocompatibil-
ity complex binding peptides in fetal thymic organ culture. J.
Exp. Med. 177:1469–1473.
6. Ashton-Rickardt, P.G. 1993. The role of peptide in the pos-22 Endogenous Peptides and Positive Selection
itive selection of CD81 T cells in the thymus. Thymus. 22:
111–115.
7. Viville, S., J. Neefjes, V. Lotteau, A. Dierich, M. Lemeur, H.
Ploegh, C. Benoist, and D. Mathis. 1993. Mice lacking the
MHC class II-associated invariant chain. Cell. 72:635–648.
8. Miyazaki, T., P. Wolf, S. Tourne, C. Waltzinger, A. Dierich,
N. Barois, H. Ploegh, C. Benoist, and D. Mathis. 1996. Mice
lacking H2-M complexes, enigmatic elements of the MHC
class II peptide-loading pathway. Cell. 84:531–541.
9. Martin, W.D., G.G. Hicks, S.K. Mendiratta, H.I. Leva, H.E.
Ruley, and L. Van Kaer. 1996. H2-M mutant mice are de-
fective in the peptide loading of class II molecules, antigen
presentation, and T cell repertoire selection. Cell. 84:543–550.
10. Fung-Leung, W.P., C.D. Surh, M. Liljedahl, J. Pang, D. Le-
turcq, P.A. Peterson, S.R. Webb, and L. Karlsson. 1996. An-
tigen presentation and T cell development in H2-M-defi-
cient mice. Science. 271:1278–1281.
11. Hogquist, K.A., S.C. Jameson, and M.J. Bevan. 1995. Strong
agonist ligands for the T cell receptor do not mediate positive
selection of functional CD81 T cells. Immunity. 3:79–86.
12. Hogquist, K.A., S.C. Jameson, W.R. Heath, J.L. Howard,
M.J. Bevan, and F.R. Carbone. 1994. T cell receptor antago-
nist peptides induce positive selection. Cell. 76:17–27.
13. Ashton-Rickardt, P.G., A. Bandeira, J.R. Delaney, L. Van
Kaer, H.P. Pircher, R.M. Zinkernagel, and S. Tonegawa.
1994. Evidence for a differential avidity model of T cell se-
lection in the thymus. Cell. 76:651–663.
14. Sebzda, E., V.A. Wallace, J. Mayer, R.S. Yeung, T.W. Mak,
and P.S. Ohashi. 1994. Positive and negative thymocyte se-
lection induced by different concentrations of a single pep-
tide. Science. 263:1615–1618.
15. Sebzda, E., T.M. Kundig, C.T. Thomson, K. Aoki, S.Y.
Mak, J.P. Mayer, T. Zamborelli, S.G. Nathenson, and P.S.
Ohashi. 1996. Mature T cell reactivity altered by peptide ag-
onist that induces positive selection. J. Exp. Med. 183:1093–
1104.
16. Hogquist, K.A., A.J. Tomlinson, W.C. Kieper, M.A. Mc-
Gargill, M.C. Hart, S. Naylor, and S.C. Jameson. 1997.
Identification of a naturally occurring ligand for thymic posi-
tive selection. Immunity. 6:389–399.
17. Hu, Q., C.R. Bazemore Walker, C. Girao, J.T. Opferman, J.
Sun, J. Shabanowitz, D.F. Hunt, and P.G. Ashton-Rickardt.
1997. Specific recognition of thymic self-peptides induces
the positive selection of cytotoxic T lymphocytes. Immunity.
7:221–231.
18. Ignatowicz, L., J. Kappler, and P. Marrack. 1996. The reper-
toire of T cells shaped by a single MHC/peptide ligand. Cell.
84:521–529.
19. Fukui, Y., T. Ishimoto, M. Utsuyama, T. Gyotoku, T. Koga,
K. Nakao, K. Hirokawa, M. Katsuki, and T. Sasazuki. 1997.
Positive and negative CD41 thymocyte selection by a single
MHC class II/peptide ligand affected by its expression level
in the thymus. Immunity. 6:401–410.
20. Surh, C.D., D.S. Lee, W.P. Fung-Leung, L. Karlsson, and J.
Sprent. 1997. Thymic selection by a single MHC/peptide
ligand produces a semidiverse repertoire of CD41 T cells.
Immunity. 7:209–219.
21. Grubin, C.E., S. Kovats, P. deRoos, and A.Y. Rudensky.
1997. Deficient positive selection of CD4 T cells in mice dis-
playing altered repertoires of MHC class II-bound self-pep-
tides. Immunity. 7:197–208.
22. Tourne, S., T. Miyazaki, A. Oxenius, L. Klein, T. Fehr, B.
Kyewski, C. Benoist, and D. Mathis. 1997. Selection of a
broad repertoire of CD41 T cells in H-2Ma0/0 mice. Immu-
nity. 7:187–195.
23. Seder, R.A., W.E. Paul, M.M. Davis, and B. Fazekas de St.
Groth. 1992. The presence of interleukin 4 during in vitro
priming determines the lymphokine-producing potential of
CD41 T cells from T cell receptor transgenic mice. J. Exp.
Med. 176:1091–1098.
24. Zal, T., A. Volkmann, and B. Stockinger. 1994. Mechanisms
of tolerance induction in major histocompatibility complex
class II–restricted T cells specific for a blood-borne self-anti-
gen. J. Exp. Med. 180:2089–2099.
25. Sen-Majumdar, A., M. Lieberman, S. Alpert, I.L. Wiessman,
and M. Small. 1992. Differentiation of CD324282 thy-
mocytes in short-term thymic stromal cell culture. J. Exp.
Med. 176:543–551.
26. Wettstein, D.A., J.J. Boniface, P.A. Reay, H. Schild, and
M.M. Davis. 1991. Expression of a class II major histocom-
patibility complex (MHC) heterodimer in a lipid-linked form
with enhanced peptide/soluble MHC complex formation at
low pH. J. Exp. Med. 174:219–228.
27. Reay, P.A., R.M. Kantor, and M.M. Davis. 1994. Use of
global amino acid replacements to define the requirements
for MHC binding and T cell recognition of moth cyto-
chrome c (93–103). J. Immunol. 152:3946–3957.
28. Nelson, A.J., R.J. Dunn, R. Peach, A. Aruffo, and A.G. Farr.
1996. The murine homolog of human Ep-CAM, a homo-
typic adhesion molecule, is expressed by thymocytes and thy-
mic epithelial cells. Eur. J. Immunol. 26:401–408.
29. Farr, A., P.C. DeRoos, S. Eastman, and A.Y. Rudensky.
1996. Differential expression of CLIP:MHC class II and con-
ventional endogenous peptide:MHC class II complexes by
thymic epithelial cells and peripheral antigen-presenting cells.
Eur. J. Immunol. 26:3185–3193.
30. Kruisbeek, A., J. Mond, B. Fowlkes, J. Carmen, S. Bridges,
and D. Longo. 1985. Absence of the Lyt-22, L3T41 lineage
of T cells in mice treated neonatally with anti-I-A correlates
with absence of intrathymic I-A bearing antigen presenting
cell function. J. Exp. Med. 161:1029–1047.
31. Kruisbeek, A.M., S. Bridges, J. Carmen, D.L. Longo, and J.J.
Mond. 1985. In vivo treatment of neonatal mice with anti-I-A
antibodies interferes with the development of the class I, class
II, and Mls-reactive proliferating T cell subset. J. Immunol.
134:3597–3604.
32. Small, M., W. Van Ewijk, A.M. Gown, and R.V. Rouse.
1989. Identification of subpopulations of mouse thymic epi-
thelial cells in culture. Immunology. 68:371–377.
33. Ho, W.Y.-W. 1995. Transgenic mouse models of T cell tol-
erance and in vitro T cell-B cell collaboration. Ph.D. thesis.
Stanford University. 183 pp.
34. Marrack, P., L. Ignatowicz, J.W. Kappler, J. Boymel, and
J.H. Freed. 1993. Comparison of peptides bound to spleen
and thymus class II. J. Exp. Med. 178:2173–2183.
35. Hunt, D.F., R.A. Henderson, J. Shabanowitz, K. Sakaguchi,
H. Michel, N. Sevilir, A.L. Cox, E. Appella, and V.H. En-
gelhard. 1992. Characterization of peptides bound to the class
I MHC molecule HLA-A2.1 by mass spectrometry. Science.
255:1261–1263.
36. Chicz, R., R. Urban, W. Lane, J. Gorga, L. Stern, D. Vig-
nali, and J. Strominger. 1992. Predominant naturally pro-
cessed peptides bound to HLA-DR1 are derived from
MHC-related molecules and are heterogeneous in size. Na-
ture. 358:764–768.
37. Bill, J., and E. Palmer. 1989. Positive selection of CD41 T23 Baldwin et al.
cells mediated by MHC class II-bearing stromal cell in the
thymic cortex. Nature. 341:649–651.
38. Anderson, G., E.J. Jenkinson, N.C. Moore, and J.J. Owen.
1993. MHC class II-positive epithelium and mesenchyme
cells are both required for T-cell development in the thymus.
Nature. 362:70–73.
39. Anderson, G., J.J. Owen, N.C. Moore, and E.J. Jenkinson.
1994. Thymic epithelial cells provide unique signals for posi-
tive selection of CD41CD81 thymocytes in vitro. J. Exp.
Med. 179:2027–2031.
40. Tanaka, Y., O. Williams, R. Tarazona, A. Wack, T. Norton,
and D. Kioussis. 1997. In vitro positive selection of alpha
beta TCR transgenic thymocytes by a conditionally immor-
talized cortical epithelial clone. Int. Immunol. 9:381–393.
41. DeKoning, J., L. DiMolfetto, C. Reilly, Q. Wei, W.L. Hav-
ran, and D. Lo. 1997. Thymic cortical epithelium is sufficient
for the development of mature T cells in relB-deficient mice.
J. Immunol. 158:2558–2566.
42. Fort, M.M., and D.M. Pardoll. 1996. Can bone marrow-
derived thymic stromal cells mediate the positive selection of
class I-restricted T cells? Cell. Immunol. 171:74–79.
43. Schonrich, G., G. Strauss, K.P. Muller, L. Dustin, D.Y. Loh,
N. Auphan, A.M. Schmitt-Verhulst, B. Arnold, and G.J.
Hammerling. 1993. Distinct requirements of positive and
negative selection for selecting cell type and CD8 interaction.
J. Immunol. 151:4098–4105.
44. Markowitz, J.S., H. Auchincloss, Jr., M.J. Grusby, and L.H.
Glimcher. 1993. Class II-positive hematopoietic cells cannot
mediate positive selection of CD41 T lymphocytes in class
II-deficient mice. Proc. Natl. Acad. Sci. USA. 90:2779–2783.
45. Laufer, T.M., J. DeKoning, J.S. Markowitz, D. Lo, and L.H.
Glimcher. 1996. Unopposed positive selection and autoreac-
tivity in mice expressing class II MHC only on thymic cor-
tex. Nature. 383:81–85.
46. Le, P.T., H.T. Maecker, and J.E. Cook. 1995. In situ detec-
tion and characterization of apoptotic thymocytes in human
thymus. Expression of bcl-2 in vivo does not prevent apop-
tosis. J. Immunol. 154:4371–4378.
47. Surh, C.D., and J. Sprent. 1994. T-cell apoptosis detected in
situ during positive and negative selection in the thymus. Na-
ture. 372:100–103.
48. Brocker, T., M. Riedinger, and K. Karjalainen. 1997. Tar-
geted expression of major histocompatibility complex
(MHC) class II molecules demonstrates that dendritic cells
can induce negative but not positive selection of thymocytes
in vivo. J. Exp. Med. 185:541–550.
49. van Meerwijk, J.P., S. Marguerat, R.K. Lees, R.N. Germain,
B.J. Fowlkes, and H.R. MacDonald. 1997. Quantitative im-
pact of thymic clonal deletion on the T cell repertoire. J.
Exp. Med. 185:377–383.
50. Burkly, L.C., S. Degermann, J. Longley, J. Hagman, R.L.
Brinster, D. Lo, and R.A. Flavell. 1993. Clonal deletion of V
beta 51 T cells by transgenic I-E restricted to thymic medul-
lary epithelium. J. Immunol. 151:3954–3960.
51. Iwabuchi, K., K. Nakayama, R.L. McCoy, F. Wang, T.
Nishimura, S. Habu, K.M. Murphy, and D.Y. Loh. 1992.
Cellular and peptide requirements for in vitro clonal deletion
of immature thymocytes. Proc. Natl. Acad. Sci. USA. 89:
9000–9004.
52. Spain, L.M., and L.J. Berg. 1994. Quantitative analysis of the
efficiency of clonal deletion in the thymus. Dev. Immunol.
4:43–53.
53. Vukmanovic, S., S.C. Jameson, and M.J. Bevan. 1994. A
thymic epithelial cell line induces both positive and negative
selection in the thymus. Int. Immunol. 6:239–246.
54. Volkmann, A., T. Zal, and B. Stockinger. 1997. Antigen-
presenting cells in the thymus that can negatively select
MHC class II-restricted T cells recognizing a circulating self
antigen. J. Immunol. 158:693–706.
55. Hugo, P., J.W. Kappler, D.I. Godfrey, and P.C. Marrack.
1994. Thymic epithelial cell lines that mediate positive selec-
tion can also induce thymocyte clonal deletion. J. Immunol.
152:1022–1031.
56. Tanaka, Y., C. Mamalaki, B. Stockinger, and D. Kioussis.
1993. In vitro negative selection of alpha beta T cell receptor
transgenic thymocytes by conditionally immortalized thymic
cortical epithelial cell lines and dendritic cells. Eur. J. Immu-
nol. 23:2614–2621.
57. Hengartner, H., B. Odermatt, R. Schneider, M. Schreyer, G.
Walle, H.R. MacDonald, and R.M. Zinkernagel. 1988. De-
letion of self-reactive T cells before entry into the thymus
medulla. Nature. 336:388–390.
58. Hugo, P., J.W. Kappler, J.E. McCormack, and P. Marrack.
1993. Fibroblasts can induce thymocyte positive selection in
vivo. Proc. Natl. Acad. Sci. USA. 90:10335–10339.
59. Pawlowski, T., J.D. Elliott, D.Y. Loh, and U.D. Staerz.
1993. Positive selection of T lymphocytes on fibroblasts. Na-
ture. 364:642–645.
60. Bix, M., and D. Raulet. 1992. Inefficient positive selection of
T cells directed by haematopoietic cells. Nature. 359:330–333.
61. Murphy, D.B., D. Lo, S. Rath, R.L. Brinster, R.A. Flavell,
A. Slanetz, and C.A. Janeway, Jr. 1989. A novel MHC class
II epitope expressed in thymic medulla but not cortex. Na-
ture. 338:765–768.
62. Inaba, K., M. Pack, M. Inaba, H. Sakuta, F. Isdell, and R.M.
Steinman. 1997. High levels of a major histocompatibility
complex II–self peptide complex on dendritic cells from the
T cell areas of lymph nodes. J. Exp. Med. 186:665–672.
63. Wülfing, C., J.D. Rabinowitz, C. Beeson, M.D. Sjaastad,
H.M. McConnell, and M.M. Davis. 1997. Kinetics and ex-
tent of T cell activation as measured with the calcium signal.
J. Exp. Med. 185:1815–1825.
64. Tanchot, C., F.A. Lemmonnier, B.P. Crarnau, A.A. Frietas,
and B. Rocha. 1997. Differential requirements for survival
and proliferation of CD8 naive or memory T cells. Science.
276:2057–2062
65. Takeda, S., H.R. Rodewald, H. Arakawa, H. Bluethmann,
and T. Shimizu. 1996. MHC class II molecules are not re-
quired for survival of newly generated CD41 T cells, but af-
fect their long-term life span. Immunity. 5:217–228.
66. Rooke, R., C. Waltzinger, C. Benoist, and D. Mathis. 1997.
Targeted complementation of MHC class II deficiency by in-
trathymic delivery of recombinant adenoviruses. Immunity.
7:123–134.
67. Kirberg, J., A. Berns, and H. von Boehmer. 1996. Peripheral
T cell survival requires continual ligation of the T cell recep-
tor to major histocompatibility complex–encoded molecules.
J. Exp. Med. 186:1269–1275.24 Endogenous Peptides and Positive Selection